Kisspeptin-10

Kisspeptin-10 is a ten-amino-acid fragment of the naturally occurring neuropeptide kisspeptin and represents the most potent, biologically active form of the kisspeptin peptide family. Produced endogenously in the hypothalamus, kisspeptin functions as the master regulatory switch for the entire hypothalamic–pituitary–gonadal (HPG) axis, operating at the very top of the reproductive hormone cascade. Rather than forcing hormone production downstream, Kisspeptin-10 works upstream in the brain to stimulate the body’s own release of gonadotropin- releasing hormone (GnRH), which in turn triggers the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These gonadotropins then act on the gonads to drive testosterone production in men and estrogen production in women—all while preserving the body’s natural hormonal feedback loops. Originally identified as a metastasis suppressor gene product (earning it the early name “metastin”), kisspeptin attracted significant scientific attention when researchers discovered that mutations in either kisspeptin or its receptor (KISS1R, also known as GPR54) result in absent or precocious puberty, confirming its indispensable role in reproductive development and sexual maturation. This landmark discovery, published in the New England Journal of Medicine in 2003 by Seminara et al., repositioned kisspeptin from oncology research into the center of reproductive endocrinology. Today, Kisspeptin-10 is under active investigation as a potential therapeutic agent for reproductive disorders including infertility, hypogonadism, and fertility preservation during testosterone replacement therapy. Unlike HCG, which acts directly on gonadal tissue, Kisspeptin-10 engages the reproductive axis at the brain level, offering a more physiological mechanism of action that supports healthy LH, FSH, and testosterone output without disrupting the body’s intrinsic regulatory signaling. A next-generation kisspeptin receptor agonist, MVT- 602 (TAK-448), is also in clinical development, exhibiting a prolonged duration of action (21–22 hours vs. 4.7 hours for native kisspeptin-54) and more closely replicating the physiological midcycle LH surge.

Peptide Information

Property Detail Full Name Kisspeptin-10 (KP-10) Other Names Metastin 45–54, KISS1 (112–121) Peptide Length 10 amino acids (decapeptide) Parent Molecule Kisspeptin-54 (metastin), encoded by the KISS1 gene Receptor KISS1R (GPR54), a G protein–coupled receptor Primary Site of Action GnRH neurons in the hypothalamus (arcuate and AVPV nuclei) Classification Endogenous neuropeptide / HPG axis regulator

Route of Administration Subcutaneous (practical); intravenous (clinical trials) Clinical Status Active human clinical trials for infertility, IVF, hypogonadism; kisspeptin-54 used clinically in the UK for IVF protocols

How It Works

Kisspeptin-10 acts at the very beginning of the hypothalamic–pituitary–gonadal (HPG) axis, the hormonal system that controls reproduction. This upstream mechanism is what distinguishes kisspeptin from downstream agents like HCG and exogenous testosterone.

The HPG Signaling Cascade

Kisspeptin-10 initiates a precise, multi-step hormonal cascade. First, Kisspeptin-10 binds to KISS1R receptors on GnRH neurons in the hypothalamus. This triggers the release of GnRH in a pulsatile pattern into the hypophyseal portal system. GnRH then travels to the anterior pituitary gland, where it stimulates gonadotroph cells to release LH and FSH. LH acts on Leydig cells in the testes to stimulate testosterone production in men and on ovarian theca cells to drive estrogen and progesterone synthesis in women. Simultaneously, FSH supports spermatogenesis in men (via Sertoli cells) and follicle development in women.

Pulsatile Nature of GnRH Release

A key feature of kisspeptin’s action is that it maintains the pulsatile nature of GnRH release. This pulsatility is critical for normal reproductive function. Continuous, non-pulsatile GnRH exposure actually suppresses gonadotropin release through GnRH receptor downregulation—this is the pharmacological principle behind GnRH agonist suppression used in prostate cancer and endometriosis treatment. Kisspeptin’s ability to enhance natural GnRH pulsatility rather than override it is what makes it attractive as a therapeutic agent. In clinical studies, Kisspeptin-10 infusion increased LH pulse frequency from 0.7 to 1.0 pulses per hour and increased secretory burst mass from 3.9 to 12.8 IU/L—demonstrating genuine enhancement of pulsatile signaling.

The Upstream Advantage

Because kisspeptin acts upstream of GnRH, it allows the body to regulate its own hormone production through natural feedback mechanisms. This contrasts fundamentally with other interventions: HCG acts directly on the gonads, bypassing the HPG axis entirely; exogenous testosterone suppresses the entire HPG axis via negative feedback; and GnRH analogs can desensitize GnRH receptors with continuous use. Kisspeptin essentially “unlocks” the body’s own hormone stores, providing a more physiological pattern of hormone release while preserving the HPTA (hypothalamic–pituitary–testicular axis) feedback architecture.

Direct Central Nervous System Effects

Beyond its endocrine role, kisspeptin has direct effects on brain regions involved in sexual behavior and emotional processing. KISS1R receptors are expressed in limbic structures including the amygdala, hippocampus, and medial preoptic area. Human fMRI studies have demonstrated that kisspeptin administration increases activation in brain areas tied to sexual arousal, attraction, and motivation—independent of testosterone changes. This central effect on sexual desire has earned kisspeptin the informal designation as a “mental Viagra,” enhancing desire and motivation rather than simply manipulating hormone numbers.

Receptor Desensitization Considerations

Studies indicate that prolonged continuous exposure to kisspeptin can lead to KISS1R receptor desensitization (tachyphylaxis), reducing effectiveness over time. This is why intermittent dosing (every two to three days rather than daily) is typically recommended in practical protocols. The desensitization phenomenon mirrors what occurs with GnRH agonists when administered continuously—the receptor system requires pulsatile, intermittent stimulation to maintain sensitivity and response.

Metabolic Cross-Talk

Emerging research has identified KISS1R expression beyond the hypothalamus, including in the pancreas, liver, and adipose tissue. Kisspeptin appears to integrate metabolic signals with reproductive function, with observed effects including improved insulin sensitivity, enhanced glucose-stimulated insulin release, and modulation of appetite signaling. This metabolic cross- talk is consistent with the well-established clinical observation that metabolic dysfunction (obesity, insulin resistance, type 2 diabetes) frequently causes secondary hypogonadism—a relationship that kisspeptin may help bridge therapeutically.

Research Benefits

Kisspeptin-10 offers a unique profile of benefits centered on its upstream, physiological mechanism of action within the HPG axis.

Restores Natural Testosterone Signaling Without Suppression

• Stimulates the hypothalamus to release GnRH, which triggers LH and FSH from the

pituitary, telling the testes to produce testosterone naturally

• Preserves the HPTA axis, unlike exogenous testosterone (TRT), which suppresses it
• In clinical studies, continuous kisspeptin-10 infusion increased testosterone from 16.6 to

24.0 nmol/L (approximately 478 to 691 ng/dL) in healthy men

• Increases LH pulse frequency and pulse amplitude, mimicking natural hormonal rhythm
• Often discussed as a fertility-preserving or pre-TRT strategy for men with secondary

hypogonadism

Supports Fertility in Men and Women

• Raises both LH and FSH—unlike HCG, which mimics LH only—directly supporting

spermatogenesis and ovulation

• Human studies demonstrate increased LH/FSH pulse frequency and amplitude
• Kisspeptin-10 increased LH and testosterone in men with type 2 diabetes and mild

hypogonadism, suggesting a therapeutic role in metabolic hypogonadism

• Kisspeptin-54 is already used clinically in UK IVF protocols to trigger oocyte maturation

with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) compared to

HCG

• Seminal kisspeptin levels correlate positively with total sperm count and motility,

suggesting a potential role in spermatogenesis

Enhances Libido and Sexual Motivation

• Directly activates limbic and attraction-related brain regions via central KISS1R

expression

• Human fMRI studies show increased activation in areas tied to sexual arousal, attraction,

and motivation—independent of testosterone changes

• In women with hypoactive sexual desire disorder (HSDD), kisspeptin enhanced sexual

brain activity and increased connectivity between emotion and arousal centers

• Cross-talk with serotonin, dopamine, and oxytocin systems further modulates mood and

sexual motivation

Improves Hormonal Rhythm and Pulsatility

• Induces physiological LH pulses that closely resemble natural GnRH rhythms
• Pulsatile signaling maintains better receptor sensitivity and produces more sustainable

endocrine responses

• This is why hormone-literate clinicians view kisspeptin as regulatory rather than

stimulatory—it enhances the body’s existing rhythms rather than overriding them

May Support Metabolic Health

• Kisspeptin receptors expressed in pancreas, liver, and adipose tissue suggest metabolic

integration

• Observed effects include improved insulin sensitivity and enhanced glucose-stimulated

insulin release

• Kisspeptin-10 restored LH and testosterone secretion in hypotestosteronemic men with

type 2 diabetes, suggesting it may help bridge the gap between metabolic dysfunction and hypogonadism

What the Science Shows

Kisspeptin-10 has strong scientific support from multiple human clinical studies—a notable advantage over many research peptides that rely solely on animal data.

George et al. (2011) – Dose-Response and LH Pulsatility in Men Journal: Journal of Clinical Endocrinology & Metabolism, 96(8), E1228–E1236 This foundational dose-response study administered intravenous bolus doses of kisspeptin-10 (0.01 to 3.0 µg/kg) to healthy men. Maximal LH stimulation occurred at the 1 µg/kg dose, with LH increasing from 4.1 to 12.4 IU/L (a three-fold increase) within 30 minutes. Notably, the 3 µg/kg dose produced a reduced response compared to 1 µg/kg, suggesting a bell-shaped dose- response curve. Continuous infusion at 4 µg/kg/h for 22.5 hours increased LH from 5.4 to 20.8 IU/L and increased testosterone from 16.6 to 24.0 nmol/L. A lower-dose infusion (1.5 µg/kg/h) increased LH pulse frequency from 0.7 to 1.0 pulses per hour and secretory burst mass from 3.9 to 12.8 IU/L. Importantly, no desensitization was observed during the 22.5-hour infusion—LH remained elevated throughout.

Dhillo et al. (2011) – Sexual Dimorphism in Kisspeptin-10 Response Journal: Journal of Clinical Endocrinology & Metabolism, 96(12), E1963–E1972 This study administered kisspeptin-10 to both healthy men (n = 11) and healthy women (n = 35) to characterize sex-specific responses. In men, IV bolus kisspeptin-10 at doses as low as 0.3 nmol/kg significantly elevated LH and FSH, with maximal LH stimulation at 10 nmol/kg. Testosterone increased significantly after 0.3 and 1.0 nmol/kg doses. In women, the response depended critically on menstrual cycle phase: women in the preovulatory phase responded robustly to kisspeptin-10 with significant LH and estradiol increases, while women in the follicular phase showed attenuated responses at lower doses but responded to higher doses via subcutaneous injection. Subcutaneous kisspeptin-10 was effective in women at doses of 4–32 nmol/kg. These findings established important sex-based and cycle-phase considerations for clinical use.

George et al. (2013) – Type 2 Diabetes and Hypogonadism Journal: Clinical Endocrinology (Proof-of-Concept Study) This proof-of-concept study examined kisspeptin-10 in five men with type 2 diabetes and mild biochemical hypogonadism (mean testosterone 8.5 nmol/L, mean BMI 40.6). Intravenous bolus kisspeptin-10 (0.3 µg/kg) increased LH comparably in diabetic men and healthy controls (LH rose from 4.7 to 10.7 IU/L in the diabetic group). Continuous infusion (4 µg/kg/h for 11 hours) increased LH from 3.9 to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L, with LH pulse frequency increasing from 0.6 to 0.9 pulses per hour. These data suggest a potential therapeutic role for kisspeptin agonists in enhancing endogenous testosterone secretion in men with type 2 diabetes and central hypogonadism.

Chan et al. (2012) – Kisspeptin Across the Menstrual Cycle

Journal: Journal of Clinical Endocrinology & Metabolism, 97(8), E1458–E1467 This study provided a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle. Kisspeptin-10 elevated LH and FSH in men at doses as low as 0.3 nmol/kg IV. In women, effects were cycle-phase dependent: preovulatory-phase women showed robust responses, while follicular-phase women did not respond at the same doses. These findings have important implications for timing of kisspeptin administration in women and for understanding the physiological fluctuations in kisspeptin sensitivity across the menstrual cycle.

Jayasena et al. (2013) – Subcutaneous Dosing in Women Journal: Journal of Clinical Endocrinology & Metabolism, 98(11), 4464–4474 Twice-daily subcutaneous injection of kisspeptin-54 (6.4 nmol/kg) did not abolish menstrual cyclicity in healthy female volunteers over the study period, demonstrating that exogenous kisspeptin administration does not disrupt normal reproductive cycling at clinically studied doses. This safety finding supports the development of kisspeptin-based therapies for women.

Seminara et al. (2003) – The Foundational Discovery

Journal: New England Journal of Medicine, 349(17), 1614–1627

This landmark paper identified loss-of-function mutations in the GPR54 gene (now KISS1R) as the cause of idiopathic hypogonadotropic hypogonadism in a consanguineous Saudi family, establishing kisspeptin signaling as obligatory for normal pubertal development and reproductive function. This discovery transformed understanding of reproductive neuroendocrinology and laid the foundation for all subsequent kisspeptin therapeutic research.

Comninos et al. / Jayasena et al. (2017–2023) – Sexual Brain Activity Multiple studies from the Dhillo laboratory at Imperial College London have used functional MRI to demonstrate that kisspeptin-54 administration enhances brain activity in regions associated with sexual arousal, attraction, and emotional processing in both men and women. In women with hypoactive sexual desire disorder, kisspeptin enhanced sexual brain activity and increased functional connectivity between limbic and arousal centers. These findings support kisspeptin’s role as a central modulator of sexual behavior beyond its endocrine effects.

MVT-602 Clinical Trials (2024) Two randomized, placebo-controlled, dose-ranging clinical trials investigated MVT-602 (TAK- 448), a kisspeptin receptor agonist with a prolonged duration of action. The LH surge induced by intermediate-dose MVT-602 (1.0 mg) more accurately replicated the physiological midcycle LH surge than any current trigger agent, closely resembling the triphasic pattern of the natural surge. These findings advance the clinical development of kisspeptin-based therapeutics for IVF and reproductive medicine.

Research Dosing Protocol

Important: Kisspeptin-10 dosing for subcutaneous use is based on clinical research extrapolation but is not yet fully standardized for therapeutic use. Clinical trials primarily used intravenous administration. Doses for subcutaneous injection must be adjusted for different

bioavailability. All dosing information below is provided for educational and research reference purposes only.

Subcutaneous Dosing Protocol

Protocol Dose Frequency Notes Starting 100 mcg Every 3 days Assess tolerance and LH response Standard 200 mcg Every 2–3 days Typical maintenance protocol TRT Adjunct 250 mcg 2–3 times weekly To preserve testicular function and fertility during TRT

Critical Dosing Principles

• Do NOT dose daily. The KISS1R receptor desensitizes with continuous stimulation,

which would reduce LH output—the opposite of the therapeutic goal.

• Intermittent dosing (every two to three days) allows receptor recovery between

administrations, maintaining effectiveness.

• Monitor LH, FSH, and testosterone levels via blood work to assess response objectively.
• Adjust dose based on laboratory results rather than symptoms alone.
• The bell-shaped dose-response curve observed in clinical studies (maximal LH at 1

µg/kg, reduced response at 3 µg/kg) suggests that more is not necessarily better.

As TRT Adjunct

• Start Kisspeptin-10 after TRT is established and stable.
• Monitor LH levels and testicular volume to confirm preserved testicular function.
• Adjust frequency based on maintaining adequate intratesticular testosterone and

spermatogenesis.

• Some practitioners combine Kisspeptin-10 with low-dose HCG or enclomiphene for

comprehensive HPG axis support.

Draw Volume Tables

5 mg vial reconstituted with 1 mL bacteriostatic water (5,000 mcg/mL):

Dose Volume Insulin Syringe Units 50 mcg 0.01 mL 1 unit 100 mcg 0.02 mL 2 units 150 mcg 0.03 mL 3 units

200 mcg 0.04 mL 4 units

Given the very small volumes above, a more dilute reconstitution is often practical: 5 mg vial reconstituted with 2 mL bacteriostatic water (2,500 mcg/mL):

Dose Volume Insulin Syringe Units 50 mcg 0.02 mL 2 units 100 mcg 0.04 mL 4 units 150 mcg 0.06 mL 6 units 200 mcg 0.08 mL 8 units

At 100 mcg three times weekly, one 5 mg vial provides approximately 16–17 doses (5–6 weeks of use).

Reconstitution Instructions

Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. Draw 1– 2 mL of bacteriostatic water into a sterile syringe. Insert the needle through the rubber stopper at an angle and direct the stream of water down the inside wall of the vial—do not spray directly onto the lyophilized powder. Allow the peptide to dissolve without aggressive shaking. Gently swirl if needed until the solution is clear and colorless. Label the vial with the date and concentration. Kisspeptin-10 dissolves readily. Discard the solution if it becomes cloudy, discolored, or contains particulate matter.

Side Effects

Kisspeptin-10 has demonstrated an excellent safety profile across multiple human clinical trials, which is a significant advantage in the peptide research landscape.

Common Side Effects (from Clinical Trials)

• Injection-site reactions: mild pain, redness, or irritation at the subcutaneous injection site
• Possible mild flushing, typically transient
• Transient changes in appetite (observed primarily in animal studies)

Clinical Safety Data

• No significant adverse events reported across multiple human studies
• Vital signs (blood pressure, heart rate) remained stable throughout dosing
• Liver function and kidney function unchanged in all clinical trials
• Full blood count and electrolytes remained within normal limits
• Well tolerated across all dose ranges studied (0.01–3.0 µg/kg IV bolus; continuous

infusions up to 22.5 hours)

• Subcutaneous kisspeptin-54 did not disrupt menstrual cyclicity in healthy women

Potential Concerns

• Receptor desensitization (tachyphylaxis): daily dosing may reduce KISS1R

responsiveness, leading to diminished LH output over time. This is the primary reason intermittent dosing is recommended.

• Hormonal fluctuations: significant LH spikes may cause transient mood or libido

variations in sensitive individuals

• Unknown long-term effects: most human studies are short-term (single-dose or days to

weeks); chronic use effects over months to years remain uncharacterized

Theoretical Risks

• HPG axis hyperstimulation is theoretically possible but unlikely at recommended

intermittent doses

• Potential effects on non-reproductive systems where KISS1R is expressed (pancreas,

liver, adipose tissue) are not fully characterized with chronic use

• Interactions with other hormone-affecting compounds have not been formally studied in

combination trials

Contraindications and Precautions

Should Avoid

• Individuals with hormone-sensitive cancers (breast, prostate, endometrial): kisspeptin

stimulates gonadotropin and sex hormone release, which could promote hormone- dependent tumor growth

• Pregnant or breastfeeding women: effects on fetal development and lactation are not

established

• Individuals with pituitary tumors or disorders: stimulation of pituitary gonadotrophs

could theoretically exacerbate pituitary pathology

• Anyone with known hypersensitivity to kisspeptin or any component of the formulation

Use with Caution

• Men with very low baseline LH: this may indicate primary pituitary dysfunction rather

than hypothalamic insufficiency, in which case kisspeptin may not be effective since it acts upstream of the pituitary

• Individuals with thyroid disorders: the HPG and hypothalamic–pituitary–thyroid axes

interact, and perturbations in one axis may affect the other

• Women: response to kisspeptin-10 is critically dependent on menstrual cycle phase;

clinical supervision is essential

• Anyone on medications affecting reproductive hormones: including GnRH

agonists/antagonists, SERMs (clomiphene, enclomiphene), aromatase inhibitors, or exogenous androgens

• Individuals with epilepsy or seizure disorders: GnRH pulsatility changes could

theoretically affect neurological function in susceptible individuals

Monitoring Recommendations

• Obtain baseline LH, FSH, and total testosterone before starting
• Repeat blood work at 4–6 weeks to assess response
• Monitor testicular size if using as a TRT adjunct (via physical exam or ultrasound)
• Adjust dose based on objective laboratory response rather than fixed protocol

Comparison with Related Compounds

Kisspeptin-10 occupies a unique upstream position in the reproductive hormone cascade, distinguishing it from other compounds commonly used for testosterone support and fertility preservation.

Compound Mechanism Primary Use LH FSH Key Distinction Effect Effect Kisspeptin-10 GnRH stimulator Fertility/TRT Strong Moderate Most physiological; (upstream, adjunct preserves full HPG hypothalamic) axis; central libido effects HCG LH mimetic (direct Fertility/TRT Direct Minimal Reliable testicular gonadal action) adjunct stimulation; bypasses HPG axis; no FSH support Gonadorelin GnRH analog Fertility/TRT Strong Moderate Acts at pituitary; (pituitary action) adjunct one step downstream of kisspeptin; desensitization risk Enclomiphene SERM (estrogen Testosterone Moderate Moderate Oral dosing; blocks receptor blockade) support hypothalamic estrogen feedback; well-studied

Kisspeptin-54 Same as KP-10 IVF Strong Moderate Clinical use in UK (longer native trigger/fertility for IVF; longer form) half-life; reduced OHSS risk MVT-602 Synthetic KISS1R IVF/fertility Strong Moderate 21–22 hour agonist (enhanced) (clinical duration of action; development) replicates physiological LH surge

Kisspeptin-10 vs. HCG

HCG directly stimulates testicular Leydig cells by mimicking LH action. Kisspeptin-10 works upstream, stimulating natural LH production from the pituitary. Kisspeptin is more physiological and stimulates both LH and FSH (HCG mimics LH only), but HCG is more reliable for direct testicular stimulation and has a longer track record in clinical practice. Many practitioners combine both: kisspeptin for HPG axis support and low-dose HCG for direct gonadal stimulation.

Kisspeptin-10 vs. Gonadorelin

Both stimulate LH and FSH, but through different levels of the axis. Gonadorelin is a GnRH analog acting directly on pituitary GnRH receptors, while kisspeptin acts one step further upstream by stimulating endogenous GnRH release from hypothalamic neurons. Both carry desensitization risk with continuous use. Kisspeptin’s additional central nervous system effects on sexual desire and motivation are not shared by gonadorelin.

Success Tips

Monitor Blood Work Objectively

Kisspeptin’s effects are measurable in standard blood tests. Obtain baseline LH, FSH, and total testosterone before starting, then recheck at four to six weeks. Adjust your protocol based on objective laboratory data rather than subjective feeling alone. The goal is demonstrable improvement in gonadotropin pulsatility and testosterone output.

Respect the Timing

Do not dose daily. The every-two-to-three-day schedule exists to prevent KISS1R receptor desensitization. More frequent dosing may paradoxically reduce effectiveness over time. Consistency with the intermittent schedule is more important than maximizing each individual dose.

Set Appropriate Expectations

Effects on testosterone are real but physiological—expect modest, natural increases rather than supraphysiological levels. The primary benefit is maintaining or restoring natural hormone production and testicular health, not maximizing absolute testosterone numbers. If supraphysiological testosterone is the goal, kisspeptin alone is not the right tool.

Combine Thoughtfully

Kisspeptin-10 can be part of a comprehensive hormone-optimization strategy: as an adjunct to TRT to preserve fertility and testicular function; combined with enclomiphene for enhanced pituitary drive; or alongside other supportive compounds. Consult a healthcare professional experienced in reproductive endocrinology before combining agents.

Address the Foundation

Kisspeptin works through the natural HPG axis. If that axis is dysfunctional due to poor sleep, chronic stress, nutritional deficiencies, excessive alcohol consumption, or metabolic disease, kisspeptin cannot fully compensate. Address these fundamentals first—kisspeptin amplifies a signal that must already be present.

Storage and Handling

Before Reconstitution (Lyophilized Powder)

• Store at −20°C (−4°F) for long-term storage
• Acceptable at 2–8°C (36–46°F) for shorter-term storage
• Protect from light and moisture
• Stable for extended periods when properly frozen

After Reconstitution

• Refrigerate at 2–8°C (36–46°F)
• Use within 4 weeks of reconstitution
• Avoid repeated freeze-thaw cycles
• Discard if solution becomes cloudy, discolored, or contains particulate matter
• Use sterile technique when drawing from the vial; avoid repeated puncturing of the

septum

Legal Status

United States

Kisspeptin-10 is not FDA-approved for any indication. It is available as a research compound from peptide suppliers. Multiple clinical trials are ongoing for reproductive applications, including infertility, IVF protocols, and hypogonadism. Kisspeptin-10 is not on the FDA’s Category 2 restricted list of banned peptides. Its regulatory path is advancing, with the next- generation agonist MVT-602 in formal clinical development.

Anti-Doping Status

Kisspeptin’s status under WADA (World Anti-Doping Agency) rules should be considered by competitive athletes. Because kisspeptin stimulates LH and FSH release, it may fall under the category of substances that manipulate the HPG axis. Athletes should verify the current prohibited list before using any kisspeptin product.

Frequently Asked Questions

How is kisspeptin different from HCG? HCG mimics LH and acts directly on the testes, bypassing the HPG axis entirely. Kisspeptin works at the brain level, stimulating the body’s own GnRH and LH production. Both can help preserve testicular function during TRT, but kisspeptin also stimulates FSH (which HCG does not) and has direct central effects on sexual desire and motivation. Can I use kisspeptin instead of TRT? Kisspeptin-10 can increase testosterone, but not to the same degree as exogenous TRT. If you have primary hypogonadism (testicular failure), kisspeptin will likely be ineffective because the testes cannot respond adequately to LH. If you have secondary hypogonadism (hypothalamic or pituitary dysfunction), kisspeptin may help restore natural testosterone production. It is most often used as an adjunct to TRT rather than a full replacement. Why can’t I take kisspeptin daily? Daily kisspeptin administration can desensitize the KISS1R receptor, leading to reduced GnRH output over time—the opposite of the intended effect. The every-two-to-three-day schedule allows receptors to resensitize between doses, maintaining effectiveness. This parallels the principle that continuous GnRH agonist exposure suppresses rather than stimulates gonadotropin release. Will kisspeptin increase my libido? Yes, through two distinct pathways. First, kisspeptin raises testosterone via the HPG axis, which supports libido indirectly. Second, and more uniquely, kisspeptin directly activates brain regions associated with sexual desire, attraction, and motivation—independent of testosterone changes. Human fMRI studies confirm enhanced sexual brain activity following kisspeptin administration. This dual mechanism is why effects on libido may be more pronounced than testosterone elevation alone would predict. Can women use Kisspeptin-10? Yes, but response depends critically on menstrual cycle phase. Women in the preovulatory phase respond robustly to kisspeptin, while women in the early follicular phase may require higher doses. Clinical use in women is primarily in IVF settings, where kisspeptin-54 is used to trigger oocyte maturation with a lower risk of ovarian hyperstimulation syndrome. Research is also exploring kisspeptin for hypothalamic amenorrhea and hypoactive sexual desire disorder. How quickly will I see results? LH elevation occurs within 30 minutes of administration based on clinical trial data. Testosterone increases follow within hours of the LH surge. Sustained improvements in baseline testosterone levels require consistent intermittent dosing over several weeks, with blood work at 4–6 weeks to confirm response. What is the difference between Kisspeptin-10 and Kisspeptin-54? Kisspeptin-10 is the minimal active fragment (10 amino acids) of the larger kisspeptin-54 (54 amino acids). Both bind to the same KISS1R receptor with full intrinsic activity. Kisspeptin-54 has a longer half-life and has been used clinically in IVF protocols. Kisspeptin-10, being smaller, may have advantages in terms of synthesis cost and formulation. The next-generation synthetic agonist MVT-602 offers an even longer duration of action (21–22 hours) and is in clinical trials.

References

1. George, J. T., Veldhuis, J. D., Roseweir, A. K., et al. (2011). Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. Journal of Clinical Endocrinology & Metabolism, 96(8), E1228–E1236. 2. Dhillo, W. S., Chaudhri, O. B., Patterson, M., et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism, 90(12), 6609–6615. 3. Dhillo, W. S., et al. (2011). The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. Journal of Clinical Endocrinology & Metabolism, 96(12), E1963–E1972. 4. Chan, Y. M., Butler, J. P., Sidhoum, V. F., Pinnell, N. E., & Seminara, S. B. (2012). Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle. Journal of Clinical Endocrinology & Metabolism, 97(8), E1458–E1467. 5. George, J. T., Veldhuis, J. D., Thalange, N. K., Sherlock, M., et al. (2013). Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clinical Endocrinology. 6. Jayasena, C. N., Comninos, A. N., Nijher, G. M., et al. (2013). Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers. Journal of Clinical Endocrinology & Metabolism, 98(11), 4464–4474.

7. Seminara, S. B., Messager, S., Chatzidaki, E. E., et al. (2003). The GPR54 gene as a regulator of puberty. New England Journal of Medicine, 349(17), 1614–1627. 8. Millar, R. P., Roseweir, A. K., Tello, J. A., et al. (2010). Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology. Brain Research, 1364, 81–89. 9. Jayasena, C. N., et al. (2023). Kisspeptin enhances sexual and emotional brain activity in women. JAMA Network Open. 10. Abbara, A., et al. (2024). MVT-602 for ovulation trigger in IVF: results from two randomized clinical trials. Clinical trials in reproductive medicine.